While we did not observe a difference in caspase 3/7+ FcγRIIB− tumor-specific CD8+ T cells (Fig. 4n, o), we found that a significantly higher frequency of FcγRIIB+ WT tumor-specific CD8+ T cells expressed caspase 3/7 compared to FcγRIIB+Fgl2−/− deficient tumor-specific CD8+ T cells (p < 0.01) (Fig. 4p, q). This evidence concerns the gene FCGR2B and neoplasm.